Despite the equal benefit from SGLT2 inhibitors independently of sex, women are less likely to receive a prescription of an SGLT2 inhibitor, even when diagnosed with DKD, HF with reduced ejection fraction, or atherosclerotic CVD. This evidence concerns the gene SLC5A2 and diabetic kidney disease.